Clinical trials: COVID-19; Immunity
Healthy Older Adults Ages 60-89
Longitudinal Innate Immunity and Aging Study
This study plans to examine biological bases of cognitive aging. The goals of the study are to better understand how immune system markers, measured in the blood and in the spinal fluid, are related to clinical features of aging…
- Trial name
- LIIA (NCT03944603)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
COVID19, Vaccination
Spike-specific Cellular Immune Response After COVID-19 Vaccination
Aim of this study is to evaluate whether COVID-19 vaccination induces a persistent cellular immune response. To this aim, blood samples are taken from vaccinated individuals and not immunized subjects as a control group.
- Conditions
- COVID19, Vaccination, Immune Response
- Trial name
- RIS-COV (NCT05102669)
- Testing
- analysis of immunological response, analysis of serum antibodies
- Where
- Italy
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele Roma
COVID-19
Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine
Rationale: Covid-19 spreads rapidly throughout the world. A large epidemic in the Netherlands would seriously challenge the available hospital capacity, and this would be augmented by absenteeism of healthcare workers (HCW).
- Trial name
- BCG-CORONA (NCT04328441)
- Testing
- BCG Vaccine
- Where
- 9 sites in Netherlands
- Volunteers
- 1,511 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht
Covid19
Biomarkers of Trained Immunity Following MMR Vaccination
This is a substudy of NCT04333732. The goal of this sub-study is to identify and characterize biomarkers of trained immunity by measuring, in vitro, immune responses to heterologous products, especially viral associated products…
- Trial name
- NCT04646239
- Testing
- Heterologous stimuli, Neutralization assay
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
COVID-19
Immune Biomarkers of Outcome From COVID-19
A new virus to humans, first identified in December 2019, is causing a global pandemic with over 1 million infections and many thousands of deaths.
- Trial name
- IBOC (NCT04436484)
- Testing
- Peripheral blood sampling
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- University Hospital Plymouth NHS Trust
COVID-19 Respiratory Infection, Influenza
Exercise and COVID-19 Viral T-cell Immunity
Viruses are a major health problem for the general public and at risk populations. Normally, detection of antibody titers is the gold standard for determining the effectiveness of the immune system following natural or vaccine…
- Trial name
- VIC (NCT05019456)
- Testing
- COVID-19 Vaccine
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Arizona
COVID-19, SARS-CoV2 Infection
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing…
- Conditions
- COVID-19, SARS-CoV2 Infection, Coronavirus Infection
- Trial name
- NECTAR (NCT05593770)
- Testing
- Fostamatinib
- Where
- 21 sites in Brazil, Germany and 3 more
- Volunteers
- 28 people
- Sponsor
- NEAT ID Foundation
COVID-19, Antibody COVID-19
The Role of Obesity in Severe COVID-19 Pathophysiology
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in millions of deaths worldwide.
- Trial name
- SAMO (NCT06968442)
- Testing
- Venipuncture
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Franciscus Gasthuis
Coronavirus Disease 2019
Long-term COVID-19 Immune Response in a Vulnerable Neighbourhood in Argentina
Between June 10t h and July 1st, a cross-sectional design study in an Argentina slum, showed a prevalence based on immunoglobuling G-class (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) of…
- Trial name
- NCT04673279
- Testing
- serology
- Where
- Argentina
- Volunteers
- 189 people
- Sponsor
- Hospital Italiano de Buenos Aires
Herpes Zoster
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent…
- Trial name
- NCT05047770
- Testing
- HZ/su, Flu D-QIV, mRNA-1273
- Where
- 46 sites in United States
- Volunteers
- 2,013 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, SARS-CoV-2
COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1
This is an open-label, controlled, single-centre pilot study of nivolumab in adult patients with COVID-19. This clinical study aims to evaluate efficacy of anti-PD1 antibody in relation to viral clearance and its safety.
- Conditions
- COVID-19, SARS-CoV-2, 2019-nCoV, Pneumonia, Viral
- Trial name
- NCT04356508
- Testing
- Nivolumab
- Volunteers
- 15 people
- Sponsor
- Dr Gerry Gin Wai Kwok
COVID-19
COVID-19 Immunity and Changes Over Time
The risk of household spread of SARS-CoV-2 hinges on both the transmission dynamics of the virus circulating in the community as well as the seroprotection pattern of constituent members, which can be attributed to vaccination…
- Trial name
- NCT05271669
- Where
- China
- Volunteers
- 1,350 people
- Sponsor
- Chinese University of Hong Kong
COVID-19, SARS-CoV-2 Infection
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
The goal of this clinical trial is to test two investigational COVID-19 booster vaccines, called CoTend-s3BXBB and CoTend-BXBB, in healthy volunteers ages 40-64.
- Trial name
- CONTENDER (NCT06810934)
- Testing
- CoTend-BXBB (SARS2-30404), CoTend-s3BXBB (SARS2-17032)
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Kara Chew
Vaccine Preventable Disease
COVID-19 Vaccine For Indirect Protection
The primary objective of this study is to test whether vaccinating adults ≥18 years in Hutterite colonies with mRNA-1273 (Moderna COVID-19) vaccine as compared to control (usual care) can prevent RT-PCR confirmed COVID-19 in…
- Trial name
- NCT04818736
- Testing
- COVID-19 Vaccination, Usual care
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- McMaster University
Virus Diseases
A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults
The purpose of this study is to assess the safety, reactogenicity and immune response of a self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike…
- Trial name
- NCT04758962
- Testing
- 1 µg CoV2 SAM (LNP)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Covid19
Mucosal Immunity in Terms of SARS-CoV-2 Antibodies in Saliva After COVID-19 Infection and Vaccination
The Primary Objective of This Single-center Study is to Investigate the SARS-CoV-2 Spike Glycoprotein RBD Antibody Concentration in Saliva and Serum in Healthy Non Vaccinated and Non-SARS-CoV-2 Infected, COVID-19 Convalescents…
- Trial name
- NCT04842305
- Testing
- Blood- and saliva tests
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Lenanrt Friis-Hansen
COVID-19
SARS-CoV-2 Infection in COVID-19 Vaccinated Patients
Vaccination of the population is crucial in the fight against the COVID-19 pandemic. Although most available vaccines have an estimated efficacy against symptomatic infection of 65-95%, this can be significantly reduced if the…
- Trial name
- COVID-IVAC (NCT05060939)
- Testing
- COVID-19 vaccinated people
- Where
- France
- Volunteers
- 1,072 people
- Sponsor
- Hospices Civils de Lyon
Coronavirus Infections, Coronavirus Sars-Associated
Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19
The present work proposes to find if a bio-active composite in the hemolymph or plasma of the freshwater bivalve Anodonta cygnea is able to offer immunity and specificity for meliorating the major symptoms in human SARS and…
- Conditions
- Coronavirus Infections, Coronavirus Sars-Associated, SARS (Severe Acute Respiratory Syndrome), COVID-19
- Trial name
- NCT05054075
- Testing
- Marine liquid and fluids, Impregnation, Incubation
- Where
- 2 sites in Portugal
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Universidade do Porto
Stress Disorder
Stress Induced by the COVID-19 Pandemic and Nonconfinement: Study of Anxiety Factors and Potential Effects on Immunity.
The aim of this project is to evaluate the impact of pandemic and nonconfinement related to anxiety and eventual immune diseases with several standardized questionnaires : Implant Stability Quotient (ISQ) , Generalized Anxiety…
- Trial name
- SCEI (NCT04491071)
- Testing
- Generalized Anxiety Disorder-7 (GAD 7), Background questionnaire, Impact of COVID-19 questionnaire
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Heart Transplantation, COVID-19 Virus Infection
Covid-19 Vaccine Response in Heart Transplant Recipients
Clinical studies indicate a decrease in vaccine efficacy in certain immunocompromised populations (kidney transplant recipients, patients undergoing chemotherapy).
- Conditions
- Heart Transplantation, COVID-19 Virus Infection, COVID-19 Vaccine
- Trial name
- COVHEART (NCT05268679)
- Testing
- Biospecimen Collection, Questionnaire, Electronic Health Record Review
- Where
- France
- Volunteers
- 190 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris